[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atrial-fibrillation-new-onset\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atrial-fibrillation-new-onset":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,75,117,142,164,192],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100503883","phase-3-short-term-anti-arrhythmic-therapy-for-post-operative-af-in-cardiac-surgery-patients-pilot-trial-100503883",false,"NCT05841056","Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients Pilot Trial","Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients (START-POAF) Pilot Trial","START-POAF","Inclusion Criteria:\n\n1. Aged ≥18 years;\n2. Have undergone cardiac surgery including CABG, valve surgery, ascending aorta replacement, or combinations thereof within 14 days of randomization;\n3. Had new-onset POAF (or flutter), documented by 12-lead ECG or lasting ≥ 1 hour on telemetry. Patients can be in AF or sinus rhythm at the time of randomization;\n4. Expected to receive 3 g - 5 g of amiodarone loading dose post-surgery.\n5. Expected to be ready for hospital discharge within 48 h of randomization.\n\nExclusion Criteria:\n\n1. Documented preoperative history of paroxysmal, persistent or permanent AF;\n2. Planned use of a class I or III anti-arrhythmic drug (other than study drug);\n3. Patients who have undergone heart transplant, complex congenital heart surgery, isolated ventricular assist device insertion, or AF ablation (surgical or catheter);\n4. Known allergy to ECG adhesives;\n5. Contraindication to amiodarone (i.e. hyperthyroidism, severe restrictive or obstructive lung disease, Long QT syndrome, PR \\> 240 ms, high-grade AV block).\n6. Individuals who are pregnant, breastfeeding, or of childbearing potential - female subjects, premenopausal who are not surgically sterile, or, if sexually active not practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; and, for those of childbearing potential, who have a positive pregnancy test at screening","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The START-POAF pilot study is a prospective, open-label two-arm, randomized controlled trial with blinded assessment of outcomes (PROBE). This pilot study will assess Atrial Fibrillation (AF) recurrence and burden in patients with new-onset AF following cardiac surgery.",[27],"Atrial Fibrillation New Onset",[29,30,31],"cardiac surgery","heart rhythm monitoring","amiodarone","RECRUITING","2026-05-22",{"date":35,"type":36},"2026-05-27","ACTUAL",{"date":38,"type":36},"2024-06-13",{"date":40,"type":21},"2028-11-30",{"name":42,"class":43},"Population Health Research Institute","OTHER",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100403070","burden-of-new-onset-atrial-fibrillation-in-patients-with-acute-myocardial-infarction-100403070","NCT04528511","BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction","BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction: the BENEFIT-AMI Multicenter Prospective Registry","BENEFIT-AMI","Inclusion Criteria:\n\n* Adult patients (\\>18 years old);\n* Patient with AMI (including STEMI and NSTEMI) who developed NOAF during the index hospitalization;\n* Patients must have received in-hospital CEM for at least 5 days;\n* Patients must give informed consent.\n\nExclusion Criteria:\n\n* Patients with a medical history of pre-existing AF;\n* Patients with a medical history of rheumatic valvular disease;\n* Patients with a medical history of sick sinus syndrome;\n* Patients undergoing emergent coronary artery bypass surgery;\n* Patients who suffer malignant tumors with an expected lifetime less than 1 year ;\n* Patients who refuse to receive CEM during hospitalization and the data of heart rhythm cannot be retrieved;\n* Patients who refuse to receive percutaneous coronary intervention (PCI) or have contraindications for PCI;\n* Patients who have died during the index hospitalization.",{"count":54,"type":21},774,"2 Years","OBSERVATIONAL","To validate the prognostic importance of the burden of new-onset atrial fibrillation (NOAF) complicating acute myocardial infarction (AMI) in a prospectively designed hospital-based registry. To characterize those factors that contribute to the progression of post-MI NOAF burden. To establish a prediction model for the risk stratification of patients with NOAF complicating AMI. To explore the clinical usefulness of NOAF burden in guiding the anticoagulation therapy among patients with post-MI NOAF.",[27,59],"Acute Myocardial Infarction",[59,61,62,63,64],"New-Onset Atrial Fibrillation","Burden","Prospective","Cardiovascular Outcomes","2026-03-16",{"date":67,"type":36},"2026-03-19",{"date":69,"type":36},"2020-10-01",{"date":71,"type":21},"2028-06-30",{"name":73,"class":43},"Shanghai 10th People's Hospital",5,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":85,"conditions":86,"keywords":93,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100589046","stroke-risk-assessment-and-markers-of-blood-clotting-in-patients-with-newly-diagnosed-non-valvular-atrial-fibrillation-nvaf-who-have-not-received-oral-anticoagulation-therapy-oac-therapy-prior-to-inclusion-100589046","NCT06949319","Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion","Individualized Stroke Risk Scores and Hemostatic Profile in Oral Anticoagulant-naïve (OAC-naïve) Patients With Non-valvular Atrial Fibrillation (NVAF)","BIO-AF","Inclusion Criteria:\n\n* Patients with newly diagnosed non-valvular atrial fibrillation (NVAF), who are oral anticoagulant-naïve (OAC-naïve) prior to inclusion.\n* Age ≥ 18 years.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Ongoing OAC treatment prior to inclusion.\n* Valvular AF (mechanical heart valves or moderate-severe mitral stenosis).\n* Secondary AF due to an acute reversible precipitant (e.g., infection, surgery, thyrotoxicosis, etc.).\n* Pregnant or breastfeeding women.\n* Treatment with oral contraceptives.\n* End-stage renal disease (creatinine clearance \\\u003C15 mL\u002Fmin as calculated by the Cockcroft-Gault equation).\n* Connective tissue diseases.\n* Active cancer (cancer diagnosis not followed by curative procedures six months from the date of diagnosis).\n* Major surgery (\\\u003C three months).\n* Acute coronary syndrome, stroke\u002FTIA, and venous thromboembolism within three months prior to inclusion.\n* Thrombophilia.\n* Significant liver disease.\n* Significant hematological disease.",{"count":84,"type":21},150,"Background:\n\nAtrial fibrillation (AF) is the most common heart rhythm disorder worldwide. Globally, there are 37.5 million people with AF. AF increases the risk of death, heart failure, and stroke, which severely affect patients and also lead to high healthcare costs. Around 25% of all strokes are caused by AF, and patients with stroke due to AF tend to have a higher risk of death and more disability compared to stroke patients without AF.\n\nStroke prevention is, therefore, an important part of AF treatment, in which blood thinning medication has an important role. However, blood thinners increase the risk of bleeding. Therefore, it is important to divide patients with AF into different risk groups, known as risk assessment, to figure out who will benefit the most from blood thinners. To be able to divide patients into different risk groups, various stroke risk assessment tools have been developed, such as the CHA2DS2-VASc score and the ABC-stroke score. The most commonly used tool is the CHA2DS2-VASc score, including only clinical risk factors, such as high blood pressure, diabetes, etc. The ABC-stroke score, which includes blood markers of heart function, has been proven to outperform the CHA2DS2-VASc score in terms of predicting stroke in AF patients. However, the CHA2DS2-VASc score remains the primary stroke risk assessment tool for AF patients in current guidelines.\n\nAfter looking at the different risk factors, patients are divided into three groups: low, intermediate, and high risk. High-risk patients must take blood-thinning medication for life, while low-risk patients do not need it. In the medium-risk group, it remains uncertain whether blood thinners should be given or not.\n\nDespite the broad use of the CHA2DS2-VASc score, the score itself has limitations. The score does not include important factors, such as the duration of AF, the size and function of the upper heart chambers, as well as the stiffness of the heart, and markers of blood clotting, which are proven markers of a state that inceases the risk of blood clots. Furthermore, the CHA2DS2-VASc score does not consider whether heart failure, high blood pressure, and diabetes are well-controlled or not, which could lead to overuse of blood thinners. Therefore, the current risk assessment tools for patients with AF are incomplete, and improvements are needed.\n\nOverall hypothesis:\n\nOverall hypothesis is that the different components of the CHA2DS2-VASc score and ABC-stroke score affect blood clotting markers differently, depending on whether conditions like heart failure, high blood pressure, and diabetes (modifiable risk factors) are well-controlled or not. Investigators also expect to see differences in blood clotting markers across different stroke risk groups (low, intermediate, and high risk, based on the CHA2DS2-VASc score and ABC-stroke score) in AF patients who have not yet started blood thinning medication. Furthermore, investigators believe that the duration of AF, the size\u002Ffunction of the upper heart chambers, as well as the stiffness of the heart, can reflect an increased risk of blood clots in AF patients.\n\nOverall goal of the study:\n\nThe overall goal of the study is to help improve the current tools used to assess the risk of stroke in patients with newly diagnosed AF. This will be done by adding more factors to the current risk assessment tools that reflect an increased risk of stroke, such as the burden of AF, the size\u002Ffunction of the heart's upper chambers, as well as the stiffness of the heart, and using biomarkers that show the blood's ability to clot as a substitute measure for stroke risk.\n\nMethods:\n\nThe study is a cross-sectional, single-center observational study and will take place at Esbjerg Hospital - University Hospital of Southern Denmark, involving collaboration between the Unit for Thrombosis Research, Department of Clinical Diagnostics and the Department of Cardiology.\n\nThe study population will consist of 150 participants with newly diagnosed AF. The participants must not be taking a specific type of blood thinner, called anticoagulant therapy (OAC-therapy), before being included in the study. The participants will be recruited with the help of the general practitioners (GPs). The general practitioners will be thoroughly informed about the study and the importance of waiting to start OAC-therapy until the participants have been seen at the cardiology outpatient clinic. The participants will be scheduled for a blood test, an ultrasound of the heart (echocardiography), and a 7-day heart rhythm monitoring within 4 days after their first meeting with the GP.",[87,88,27,89,90,91,92],"Atrial Fibrillation (AF)","Atrial Fibrillation (Prevention of Stroke)","Non Valvular Atrial Fibrillation","Stroke (in Patients With Atrial Fibrillation)","Stroke","Thrombosis",[94,95,96,97,98,99,100,101,102,103,104,91,105,106],"Stroke risk assessment in patients with atrial fibrillation","OAC-naïve patients with newly diagnosed atrial fibrillation","Hemostatic biomarkers","CHA2DS2-VASc score","ABC-stroke score","AF-burden","Left Atrial Function Index (LAFI)","Echocardiography","HFA-PEFF score","H2FPEF score","Heart failure with preserved ejection fraction (HFpEF)","Oral anticoagulant therapy","Non-valvular atrial fibrillation","2025-04-21",{"date":109,"type":36},"2025-04-29",{"date":111,"type":36},"2024-08-16",{"date":113,"type":21},"2025-09",{"name":115,"class":43},"Nedim Tojaga",1,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":116},"100571069","phase-2-empa-esus-a-randomised-control-trial-to-investigate-the-impact-of-empagliflozin-on-left-atrial-function-in-patients-with-embolic-stroke-of-undetermined-source-100571069","NCT06715449","EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source","EMPA-ESUS","Inclusion Criteria:\n\n* Age over 18 years\n* Patient has had an embolic stroke of undetermined source, defined as:\n\n  * Ischaemic stroke or transient ischaemic attack diagnosed clinically + supporting radiological features on CT or MRI imaging\n  * No clinically significant extracranial or intracranial atherosclerosis found on neck imaging\n  * No evidence of prevalent cardioembolic source of embolism - atrial dysrhythmia, cardiac thrombus, prosthetic valve, cardiac tumours, mitral stenosis, recent MI, LVEF\\\u003C35%, valvular vegetations, or infective endocarditis\n\nAND\n\n* No other specific stroke aetiology identified (pro-thrombotic states, arteritis, dissection, drug abuse)\n* Patient has been referred for an implantable loop recorder implant to investigate possible atrial dysrhythmia\n* Ability to give written, informed consent\n\nExclusion Criteria:\n\n* Prevalent atrial fibrillation or atrial flutter\n* Subsequent demonstration of a cardio-emoblic source\n* Pre-existent indication for SGLT2i including heart failure with a reduced ejection fraction and Type 1 or Type 2 diabetes mellitus\n* Contraindication to the commencement of SGLT2i including a history of, or risk factors for diabetic ketoacidosis, such as restricted food intake or a history of alcohol abuse\n* Hypersensitivity to the active substance or to any of the excipients of empagliflozin\n* Presence of alternate implantable cardiac devices such as a pacemaker or defibrillator, that would make ILR utilisation redundant\n* Any condition that may confound the results or interfere with participation such as dementia\n* An unwillingness to participate",{"count":125,"type":21},100,[127,24],"PHASE2","Atrial fibrillation (AF) is the most common heart rhythm problem in the adult population. There is a five-fold increase in stroke risk in patients with AF. Whilst there has been considerable advances in AF management including improvement in ablation therapy, preventing AF remains an unmet need.\n\nOne promising avenue is a group of medications called Sodium Glucose Cotransporter 2 (SGLT2) inhibitors, which has been studied in people with diabetes, kidney disease and weak heart muscle. These medicines were consistently found to lower the risk of developing AF. This can be promising for patients who have suffered a stroke for unclear reasons, where a significant proportion are subsequently found to have short periods of AF. Often prior to AF development, patients may have changes in the structure or function of the top chambers of their heart (the atria). This may provide a useful marker for us to understand whether SGLT2i impacts AF risk.\n\nAim of research study:\n\nThe aim of this study is to investigate whether the use of the drug empagliflozin, an SGLT2 inhibitor, prevents changes in the left atrium associated with future AF development. Using advanced imaging techniques and continuous rhyth monitoring we intend to study the effect of SGLT2 inhibitors on left atrial function and arrhythmia occurence.\n\nStudy design:\n\nPatients who are undergoing an implantable loop recorder insertion, to detect AF following a stroke, will be invited for participation. Eligible consenting patients will have a baseline assessment with echocardiography, electrocardiogram and anthropometric measures. They will then be randomised to receive either the SGLT2i alongside usual stroke care for 6 months, or usual stroke care alone. All patients will be monitored remotely via their loop recorder, and will undergo repeat electrocardiogpahic, echocardiographic and anthropometric assessment at 6 months. This way, we aim to investigate whether the SGLT2 inhibitor causes changes in atrial parameters that may be associated with future AF development.",[130,27],"Embolic Stroke of Undetermined Source",[132],"Atrial strain","2024-11-28",{"date":135,"type":36},"2024-12-04",{"date":137,"type":36},"2024-11-22",{"date":139,"type":21},"2029-03",{"name":141,"class":43},"University of East Anglia",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":148,"targetDuration":150,"studyType":56,"phases":4,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":44},"100520375","long-term-evaluation-of-cardiac-arrhythmias-after-transcatheter-aortic-valve-implantation--the-locate-registry-100520375","NCT06055751","Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Implantation -The LOCATE Registry","Inclusion Criteria:\n\n* Patients \\> 18 years of age with severe aortic stenosis that undergo TAVI for severe aortic stenosis that develop any one of the following conduction system abnormalities on the immediate post procedural or post operative ECG and have undergone ILR implantation for long-term monitoring of these conditions:\n* New left bundle branch block (QRS \\>120ms)\n* New first degree AV block (PR\\>200ms) or worsening of pre-existing first-degree AV block by \\>30ms\n* New right bundle branch block (QRS\\>120ms)\n* Intra-procedural 2:1 or higher-grade AV block with spontaneous improvement within 24 hours\n\nExclusion Criteria:\n\n* Patients with high grade or complete AV block post TAVI needing urgent pacemakers\n* Patient with existing cardiac implantable electronic devices (CIEDs)\n* Patients having a particular medical condition that dictates that they cannot tolerate subcutaneous, chronically-inserted device\n* Patient is currently pregnant as evidenced by urine positive Beta-HCG. (Urine Beta human chorionic gonadotropin (HCG) will be checked in all females of the reproductive age group).\n* Patients not willing to sign the consent, lacks the capacity to sign the consent or revoke the consent after signing will be excluded",{"count":149,"type":21},50,"12 Months","The purpose of the Long term Evaluation of Cardiac Arrhythmias after Transcatheter Aortic Valve Implantation (LOCATE) Registry is to perform long-term ambulatory monitoring of patients with severe aortic stenosis who undergo trans-catheter aortic valve implantation (TAVI) and develop new onset conduction system abnormalities post-procedure that do not require urgent permanent pacemaker (PPM) implantation. The primary objectives of this study are to assess the incidence of late onset heart block necessitating PPM implantation and to evaluate the incidence of new onset atrial fibrillation (AF) following TAVI. This study aims to provide valuable insights into the long-term cardiac health of TAVI patients and inform the development of improved treatment strategies for aortic stenosis patients with conduction system abnormalities.",[153,27,154],"Aortic Stenosis","Heart Block","2024-10-14",{"date":157,"type":36},"2024-10-16",{"date":159,"type":36},"2023-09-22",{"date":161,"type":21},"2025-12",{"name":163,"class":43},"Kansas City Heart Rhythm Research Foundation",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":171,"sex":17,"minAge":172,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":175,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":4},"100551341","promoting-atrial-fibrillation-screening-in-primary-care-100551341","NCT06458829","Promoting Atrial Fibrillation Screening in Primary Care","Effects of an Implementation Program to Promote Atrial Fibrillation Screening in Primary Care Centers in China","Inclusion Criteria:\n\n* aged 65 years or above\n* living in community\n\nExclusion Criteria:\n\n* with a previous confirmed diagnosis of atrial fibrillation\n* with implanted ICD or pacemaker\n* unable to provide consent\n* involving in other atrial fibrillation screening program",true,"65 Years",{"count":174,"type":21},4800,[176],"NA","Atrial fibrillation is the most common sustained cardiac arrhythmia in adults. Due to the asymptomatic and paroxysmal nature (randomly and shortly occurring of atrial fibrillation, and can therefore remain unnoticed) of atrial fibrillation. Atrial fibrillation increases the risk of stroke five fold if left untreated.\n\nScreening in old populations above age 65 years is helpful to find more atrial fibrillation cases. However, screening for atrial fibrillation is not well implemented in China. Thus, this project aims to promote atrial fibrillation screening in primary care centers in China. We will develop an intervention program (SEARCH-AF) and examine the effects (including the clinical effects and implementation effects) of program.",[27],[180,181],"Atrial Fibrillation","Disease screening","NOT_YET_RECRUITING","2024-06-10",{"date":185,"type":36},"2024-06-14",{"date":187,"type":21},"2024-07-01",{"date":189,"type":21},"2026-12-30",{"name":191,"class":43},"Sun Yat-sen University",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":17,"minAge":198,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":44},"100537259","strokestop-iii---optimized-method-for-atrial-fibrillation-screening-100537259","NCT06275503","STROKESTOP III - Optimized Method for Atrial Fibrillation Screening","Inclusion Criteria:\n\n* Individuals aged 75\u002F76 in 2024 (born 1948, 1949)\n* Must reside in the region of Värmland\n* Must be listed at a primary care facility\n\nExclusion Criteria:\n\n* Treatment with oral anti coagulation treatment (OAC)\n* Contraindications for OAC treatment\n* Prior atrial fibrillation\n* Unable to provide consent","75 Years","76 Years",{"count":201,"type":21},2200,[176],"Atrial fibrillation is the most common sustained cardiac arrhythmia affecting more than 3% of the adult population. The symptoms of atrial fibrillation can range from asymptomatic to debilitating. It can be permanent in its nature, but also paroxysmal with only short bursts of atrial fibrillation randomly occurring and can therefore remain unnoticed. Atrial fibrillation increases the risk of stroke five fold if left untreated.\n\nScreening for atrial fibrillation in elderly populations above age 65 years can result in detection of new atrial fibrillation cases ranging from 0,5% new AF with a single time-point ECG, up to 30% AF if an implantable loop recorder is inserted for 3 years.\n\nCurrently opportunistic screening using pulse palpation, or a single time-point ECG is recommended by the European Society of Cardiology guidelines. Systematic screening in individuals aged 75 or above, or at a high stroke risk should be considered.\n\nOverall, participation in systematic atrial fibrillation screening trials has been shown to be relatively low with almost 50% non-participants. Participants are generally healthier, with higher socioeconomic status, hence the ones who would potentially benefit the most remain absent.\n\nOpportunistic screening has shown promising results with higher participation rates and the possibility of better outreach. There is a lack of data from randomized trials on the difference in participation rates in systematic and opportunistic screening approaches when screening with prolonged ECG monitoring.",[180,27],"2024-05-03",{"date":207,"type":36},"2024-05-06",{"date":209,"type":36},"2024-05-02",{"date":211,"type":21},"2026-06-30",{"name":213,"class":43},"Danderyd Hospital"]